Advertisement
Please see important full U.S. Prescribing Information, and the MedicationGuides for INTRON(R) A and peginterferon alfa-2b at www.schering-plough.com.
Advertisement
Schering-Plough Corp. has exclusive ex-U.S. marketing rights to CAELYX(R),except in Japan and Israel, through a distribution agreement with ALZA, awholly owned subsidiary of Johnson & Johnson, New Brunswick, N.J., USA. Theproduct is marketed in the United States under the tradename DOXIL(R) by OrthoBiotech Products, L.P. Full EU Prescribing Information may be accessed atwww.emea.europa.eu/humandocs/PDFs/EPAR/Caelyx/H-089-PI-en.pdf.
About Schering-Plough
Schering-Plough is an innovation-driven, science-centered global healthcare company. Through its own biopharmaceutical research and collaborationswith partners, Schering-Plough creates therapies that help save and improvelives around the world. The company applies its research-and-developmentplatform to human prescription and consumer products as well as to animalhealth products. Schering-Plough's vision is to "Earn Trust, Every Day" withthe doctors, patients, customers and other stakeholders served by itscolleagues around the world. The company is based in Kenilworth, N.J., andits Web site is www.schering-plough.com.
SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press releaseincludes certain "forward-looking statements" within the meaning of thePrivate Securities Litigation Reform Act of 1995, including statementsrelating to the potential market and the clinical development of its oncologyportfolio. Forward-looking statements relate to expectations or forecasts offuture events. Schering-Plough does not assume the obligation to update anyforward-looking statement. Many factors could cause actual results to differmaterially from Schering-Plough's forward-looking statements, including marketforces, economic factors, product availability, patent and other intellectualproperty protection, current and future branded, generic or over-the-countercompetition, the regulatory process, and any developments following regulatoryapproval, among other uncertainties. For further details about these andother factors that may impact the forward-looking statements, seeSchering-Plough's Securities and Exchange Commission filings, including PartI, Item 1A, "Risk Factors" in Schering-Plough's 2008 Q1 10-Q.-- TEMODAR(R): Twenty-eight abstracts will be presented, including 10 poster discussions and eight oral presentations. -- CAELYX(R): Eleven abstracts will be presented, including two poster discussions and two oral presentations. -- INTRON(R) A and peginterferon alfa-2b: Data will be featured in more than 10 abstracts, including five poster discussions and five oral presentations.
SOURCE Schering-Plough Corporation
